On March 30, 2021 Ikena Oncology, Inc. (IKNA), a targeted oncology company currently developing an EP4 antagonist (AAT-007) in the clinic originally licensed from AskAt Inc., reported that debuted on the NASDAQ market on March 26, 2021 (Press release, AskAt, MAR 30, 2021, View Source [SID1234577324]). The company sold 7,812,500 shares at $16 each, then doubled in value over the first day of trading, closing at $32. According to Ikena Oncology’s prospectus, it will allocate approximately $10-15 million from the offering proceeds to the development of AAT-007.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!